scPharmaceuticals (SCPH) Competitors $4.85 +0.28 (+6.13%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$4.85 0.00 (0.00%) As of 08/22/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SCPH vs. CRMD, MLYS, NUVB, ORIC, IOVA, SION, TRVI, URGN, CRON, and IMNMShould you be buying scPharmaceuticals stock or one of its competitors? The main competitors of scPharmaceuticals include CorMedix (CRMD), Mineralys Therapeutics (MLYS), Nuvation Bio (NUVB), Oric Pharmaceuticals (ORIC), Iovance Biotherapeutics (IOVA), Sionna Therapeutics (SION), Trevi Therapeutics (TRVI), Urogen Pharma (URGN), Cronos Group (CRON), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry. scPharmaceuticals vs. Its Competitors CorMedix Mineralys Therapeutics Nuvation Bio Oric Pharmaceuticals Iovance Biotherapeutics Sionna Therapeutics Trevi Therapeutics Urogen Pharma Cronos Group Immunome CorMedix (NASDAQ:CRMD) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings. Do analysts recommend CRMD or SCPH? CorMedix presently has a consensus price target of $16.71, suggesting a potential upside of 22.09%. scPharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 188.66%. Given scPharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe scPharmaceuticals is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88scPharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CRMD or SCPH more profitable? CorMedix has a net margin of 42.11% compared to scPharmaceuticals' net margin of -183.55%. CorMedix's return on equity of 42.73% beat scPharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets CorMedix42.11% 42.73% 34.19% scPharmaceuticals -183.55%-1,647.86%-71.76% Does the media prefer CRMD or SCPH? In the previous week, scPharmaceuticals had 1 more articles in the media than CorMedix. MarketBeat recorded 1 mentions for scPharmaceuticals and 0 mentions for CorMedix. scPharmaceuticals' average media sentiment score of 1.93 beat CorMedix's score of 1.00 indicating that scPharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment CorMedix Positive scPharmaceuticals Very Positive Which has more risk & volatility, CRMD or SCPH? CorMedix has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Which has preferable valuation & earnings, CRMD or SCPH? CorMedix has higher revenue and earnings than scPharmaceuticals. scPharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorMedix$43.47M23.51-$17.93M$0.7518.25scPharmaceuticals$36.33M7.12-$85.15M-$1.81-2.68 Do insiders and institutionals hold more shares of CRMD or SCPH? 34.2% of CorMedix shares are owned by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are owned by institutional investors. 5.3% of CorMedix shares are owned by insiders. Comparatively, 4.8% of scPharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryCorMedix beats scPharmaceuticals on 12 of the 17 factors compared between the two stocks. Get scPharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPH vs. The Competition Export to ExcelMetricscPharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$258.50M$3.11B$5.81B$9.76BDividend YieldN/A2.23%4.39%4.06%P/E Ratio-2.6821.0031.3626.05Price / Sales7.12209.44387.8788.42Price / CashN/A44.5038.0259.36Price / Book-12.138.129.536.60Net Income-$85.15M-$54.72M$3.26B$265.65M7 Day Performance5.43%2.62%2.14%2.00%1 Month Performance-16.95%3.25%3.22%0.46%1 Year Performance-9.68%10.82%30.18%18.88% scPharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPHscPharmaceuticals4.5381 of 5 stars$4.85+6.1%$14.00+188.7%-9.7%$258.50M$36.33M-2.6830Positive NewsShort Interest ↓CRMDCorMedix2.6414 of 5 stars$13.10+1.3%$16.71+27.6%+142.3%$965.21M$43.47M17.4730MLYSMineralys Therapeutics3.2649 of 5 stars$15.34+5.6%$32.25+110.2%+28.3%$962.61MN/A-4.3128News CoveragePositive NewsAnalyst UpgradeNUVBNuvation Bio2.3351 of 5 stars$2.90+5.5%$7.33+152.9%+0.2%$941.25M$7.87M-4.6060ORICOric Pharmaceuticals4.8149 of 5 stars$9.90+2.5%$17.63+78.0%+1.5%$938.21MN/A-5.2480IOVAIovance Biotherapeutics4.6165 of 5 stars$2.50-2.0%$11.90+376.0%-77.3%$922.73M$164.07M-2.03500News CoverageAnalyst ForecastShort Interest ↓SIONSionna Therapeutics1.8754 of 5 stars$21.39+2.7%$38.50+80.0%N/A$918.99MN/A0.0035News CoverageHigh Trading VolumeTRVITrevi Therapeutics3.0791 of 5 stars$7.45-0.9%$20.38+173.5%+152.5%$915.76MN/A-17.7420Analyst ForecastURGNUrogen Pharma4.5389 of 5 stars$19.40-1.6%$31.43+62.0%+37.3%$911.87M$90.40M-5.84200CRONCronos Group0.4007 of 5 stars$2.53+6.8%N/A+11.1%$907.80M$117.61M50.60450IMNMImmunome1.8134 of 5 stars$10.25-0.3%$23.14+125.8%-33.3%$894.82M$9.04M-3.3340News CoverageAnalyst ForecastGap Up Related Companies and Tools Related Companies CorMedix Alternatives Mineralys Therapeutics Alternatives Nuvation Bio Alternatives Oric Pharmaceuticals Alternatives Iovance Biotherapeutics Alternatives Sionna Therapeutics Alternatives Trevi Therapeutics Alternatives Urogen Pharma Alternatives Cronos Group Alternatives Immunome Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCPH) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share scPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access